JERRY A NICK, MD
Osteopathic Medicine at Jackson St, Denver, CO
License number
Colorado 33482
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
1400 Jackson St, Denver, CO 80206
Phone
(303) 388-4461
(303) 270-2174 (Fax)
(303) 270-2174 (Fax)
Personal information
See more information about JERRY A NICK at radaris.comName
Address
Phone
660 Krameria St, Denver, CO 80220
4200 9Th Ave, Denver, CO 80220
4200 9Th Ave, Denver, CO 80220
Denver, CO
660 Krameria St, Denver, CO 80220
Professional information
Dr. Jerry Nick, Denver CO - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
National Jewish Health
1400 Jackson St, Denver 80206
(303) 388-4461 (Phone), (303) 398-1476 (Fax)
1400 Jackson St, Denver 80206
(303) 388-4461 (Phone), (303) 398-1476 (Fax)
Certifications:
Critical Care Medicine, 2007, Internal Medicine, 2002, Pulmonary Disease, 1996
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
National Jewish Health
1400 Jackson St, Denver 80206
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
National Jewish Health
1400 Jackson St, Denver 80206
1400 Jackson St, Denver 80206
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
National Jewish Health
1400 Jackson St, Denver 80206
Education:
Medical School
University Of Washington School Of Medicine
Graduated: 1989
University Of Washington Program
Graduated: 1990
Graduated: 1992
University Of Colorado Denver
Graduated: 1997
University Of Washington School Of Medicine
Graduated: 1989
University Of Washington Program
Graduated: 1990
Graduated: 1992
University Of Colorado Denver
Graduated: 1997
Jerry Allan Nick, Aurora CO
Specialties:
Internal Medicine, Critical Care Medicine, Pulmonary Disease, Critical Care Medicine
Work:
University of Colorado Hospital
12605 E 16Th Ave, Aurora, CO 80045 Main Campus
1400 Jackson St, Denver, CO 80206
12605 E 16Th Ave, Aurora, CO 80045 Main Campus
1400 Jackson St, Denver, CO 80206
Education:
University of Washington (1989)
Professor At National Jewish Health
Location:
Greater Denver Area
Industry:
Hospital & Health Care
Professor At National Jewish Health
Location:
Greater Denver Area
Industry:
Hospital & Health Care
Product And Process For Inhibition Of Biofilm Development
US Patent:
2008020, Aug 28, 2008
Filed:
May 6, 2008
Appl. No.:
12/115880
Inventors:
Jerry A. Nick - Denver CO, US
Travis S. Walker - Denver CO, US
G. Scott Worthen - Denver CO, US
Travis S. Walker - Denver CO, US
G. Scott Worthen - Denver CO, US
Assignee:
NATIONAL JEWISH MEDICAL AND RESEARCH CENTER - Denver CO
International Classification:
A61K 31/7076
US Classification:
514 44
Abstract:
Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.
Product And Process For Inhibition Of Biofilm Development
US Patent:
2006003, Feb 9, 2006
Filed:
Aug 4, 2005
Appl. No.:
11/197897
Inventors:
Jerry Nick - Denver CO, US
Travis Walker - Denver CO, US
G. Worthen - Denver CO, US
Travis Walker - Denver CO, US
G. Worthen - Denver CO, US
Assignee:
National Jewish Medical and Research Center - Denver CO
International Classification:
A61K 48/00, A61K 31/7076, A61K 31/7072, A61K 31/522
US Classification:
514044000, 514045000, 514049000, 514263310
Abstract:
Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.
Markers For Diagnosis Of Pulmonary Inflammation And Methods Related Thereto
US Patent:
2014000, Jan 2, 2014
Filed:
May 16, 2013
Appl. No.:
13/895921
Inventors:
Jerry Nick - Denver CO, US
Assignee:
National Jewish Health - Denver CO
International Classification:
C12Q 1/68
US Classification:
514 31, 514 23
Abstract:
The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.
Markers For Diagnosis Of Pulmonary Inflammation And Methods Related Thereto
US Patent:
2009023, Sep 17, 2009
Filed:
Mar 10, 2009
Appl. No.:
12/401381
Inventors:
Milene Saavedra - Denver CO, US
Jerry Nick - Denver CO, US
Jerry Nick - Denver CO, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.
Methods And Compositions For The Disruption Of Biofilms
US Patent:
2008019, Aug 21, 2008
Filed:
Feb 14, 2008
Appl. No.:
12/031029
Inventors:
Jerry A. Nick - Denver CO, US
Quinn M. Parks - Denver CO, US
Quinn M. Parks - Denver CO, US
Assignee:
NATIONAL JEWISH MEDICAL AND RESEARCH CENTER - Denver CO
International Classification:
A61K 9/00, A61K 38/02, A01N 43/48, A61P 31/04, A01P 1/00, A01N 37/18, A61K 38/16
US Classification:
424423, 514 2, 514 12, 514 44
Abstract:
The invention relates to methods of inhibiting biofilm formation or reducing biofilms in a subject or on a device or surface by administering a charged compound such as a polyamino acid to a subject, device or surface. The invention also relates to compositions for inhibiting biofilm formation or reducing biofilms.
Markers For Diagnosis Of Pulmonary Inflammation And Methods Related Thereto
US Patent:
8465923, Jun 18, 2013
Filed:
Dec 16, 2011
Appl. No.:
13/328886
Inventors:
Milene Saavedra - Denver CO, US
Jerry Nick - Denver CO, US
Jerry Nick - Denver CO, US
Assignee:
National Jewish Health - Denver CO
International Classification:
C12Q 1/68, C07H 21/02, C07H 21/04
US Classification:
435 611, 435 61, 435 613, 435 617, 435 618, 536 235, 536 2431
Abstract:
The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA 112, CSPG2, TLR2, and CD163.